亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

医学 细胞因子释放综合征 嵌合抗原受体 内科学 肿瘤科 CD8型 T细胞 免疫学 抗原 胃肠病学 免疫疗法 免疫系统 癌症
作者
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau‐Florea,Dalia Salem,Hao‐Wei Wang,Constance M. Yuan,Maryalice Stetler‐Stevenson
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:38 (17): 1938-1950 被引量:328
标识
DOI:10.1200/jco.19.03279
摘要

PURPOSE Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells. PATIENTS AND METHODS We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22 CAR T-cell persistence, and cytokine profiling. RESULTS Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis–like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation. CONCLUSION In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lbw完成签到 ,获得积分10
1秒前
KK完成签到,获得积分10
59秒前
llynvxia发布了新的文献求助10
59秒前
科研通AI5应助科研通管家采纳,获得30
1分钟前
孟筱完成签到 ,获得积分10
2分钟前
2分钟前
Zzz_Carlos完成签到 ,获得积分10
2分钟前
沉默碧空完成签到,获得积分10
2分钟前
晓晓完成签到 ,获得积分10
3分钟前
3分钟前
jisidehuli发布了新的文献求助10
4分钟前
4分钟前
SYQ发布了新的文献求助30
4分钟前
jisidehuli完成签到,获得积分10
4分钟前
SRn嘿嘿完成签到,获得积分10
4分钟前
SYQ完成签到,获得积分10
4分钟前
zr完成签到 ,获得积分10
4分钟前
4分钟前
mingjie发布了新的文献求助10
4分钟前
mingjie完成签到,获得积分10
4分钟前
烦烦完成签到 ,获得积分20
5分钟前
5分钟前
Milton_z完成签到 ,获得积分10
5分钟前
麋鹿发布了新的文献求助10
5分钟前
上官凯凯完成签到 ,获得积分10
5分钟前
6分钟前
FashionBoy应助小短腿飞行员采纳,获得10
6分钟前
ZZ发布了新的文献求助10
6分钟前
6分钟前
6分钟前
ZZ完成签到,获得积分10
6分钟前
小短腿飞行员完成签到,获得积分10
6分钟前
所所应助科研通管家采纳,获得10
7分钟前
7分钟前
7分钟前
啊啊啊完成签到 ,获得积分10
7分钟前
不倦应助yiban采纳,获得10
7分钟前
隐形的尔珍完成签到,获得积分10
7分钟前
小白菜完成签到,获得积分10
7分钟前
Hans完成签到,获得积分10
8分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571244
求助须知:如何正确求助?哪些是违规求助? 3141865
关于积分的说明 9444761
捐赠科研通 2843299
什么是DOI,文献DOI怎么找? 1562814
邀请新用户注册赠送积分活动 731243
科研通“疑难数据库(出版商)”最低求助积分说明 718507